Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...
A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results